Overview

ELB139 Given Orally to Patients With Concurrent Panic Disorder, Challenged by CO2 Inhalation After a Single Dose and One Week of Treatment

Status:
Terminated

Trial end date:
2006-10-01

Target enrollment:

Participant gender:

Summary

This study is designed to investigate if 600 mg ELB139 given orally t.i.d. to patients suffering from panic disorder is effective in reducing anxiety evoked by inhalation of 35% CO2 measured by a visual analogue scale after the first intake and after approximately one week of treatment as compared to placebo treatment.

Phase:

Phase 2

Details

Lead Sponsor:

elbion AG

Treatments:

1-(4-chlorophenyl)-4-piperidin-1-yl-1,5-dihydroimidazol-2-one